# Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

> **NCT01153698** · — · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 167 (actual)

## Conditions studied

- Venous Thromboembolism
- Arthroplasty, Replacement

## Interventions

- **DRUG:** dabigatran

## Key facts

- **NCT ID:** NCT01153698
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2011-12-21
- **Final completion:** 2011-12-21
- **Target enrollment:** 167 (ACTUAL)
- **Why stopped:** This trial was prematurely discontinued due to low enrolment.
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01153698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01153698, "Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01153698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*